You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BCMA X CD3 T Cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Multiple Myeloma Trial (BCMA CAR T cells, BCMA/CD19 CAR T cells)

Enrolling by invitation
  • Multiple Myeloma
  • BCMA CAR T cells
  • BCMA/CD19 CAR T cells
  • London, County (optional), United Kingdom
    University College London Hospital
Sep 15, 2022

Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

Not yet recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • GC012F
  • (no location specified)
Apr 28, 2023

Multiple Myeloma Trial (BCMA-TGFß CAR-T cells (0.75 x10^6 cells/kg), BCMA-TGFß CAR-T cells (1 x 10^6 cells/kg), BCMA-TGFß CAR-T

Not yet recruiting
  • Multiple Myeloma
  • BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)
  • +3 more
  • (no location specified)
Jul 28, 2023

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) Trial in Zhongshan (BCMA-CD19 cCAR T cells)

Recruiting
  • Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)
  • BCMA-CD19 cCAR T cells
  • Zhongshan, Guangdong, China
    Zhongshan People's Hospital
Jul 23, 2022

CAR-T Cell Therapy Trial in Shanghai (GC012F injection)

Recruiting
  • CAR-T Cell Therapy
  • GC012F injection
  • Shanghai, Shanghai, China
    Department of Rheumatology, Ren Ji Hospital South Campus, School
May 5, 2023

Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Columbus (procedure, drug, biological)

Not yet recruiting
  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma
  • Biospecimen Collection
  • +9 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 1, 2023

Multiple Myeloma Trial (Linvoseltamab)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Apr 12, 2023

Multiple Myeloma Trial in Spain (REGN5458, Daratumumab, Carfilzomib)

Recruiting
  • Multiple Myeloma
  • Athens, Greece
  • +8 more
Nov 30, 2022

Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Spain (ARI0003)

Not yet recruiting
  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • ARI0003
  • Santiago De Compostela, A Coruña, Spain
  • +6 more
Oct 24, 2023

Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma Trial in Taiyuan (CAR-T Autologous T cell injection)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • CAR-T Autologous T cell injection
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Dec 2, 2022

Adult Patients Treated in Study R5459-RT-1944 Who Receive A

Not yet recruiting
  • Chronic Kidney Disease (CKD)
  • Noninterventional
  • (no location specified)
Nov 21, 2022

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023

Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

Not yet recruiting
  • Non Hodgkin's Lymphoma
  • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
  • +2 more
  • Beijing, China
  • +2 more
Aug 23, 2023

Chronic GVHD, Hematologic and Lymphocytic Disorder, Steroid Refractory GVHD Trial in Duarte (procedure, biological, other)

Not yet recruiting
  • Chronic Graft Versus Host Disease
  • +2 more
  • Biopsy
  • +11 more
  • Duarte, California
    City of Hope Medical Center
Aug 7, 2023

High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin

Not yet recruiting
  • High Grade B-Cell Non-Hodgkin's Lymphoma
  • +3 more
  • Anti-CD19-CAR CMV-specific T-lymphocytes
  • +9 more
  • Duarte, California
    City of Hope Medical Center
Apr 5, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
  • +4 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin
Sep 22, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5

Completed
Has Results
  • Lymphoma, Non-Hodgkin
  • +3 more
  • CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
  • +3 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & Medical College of Wisconsin
Jun 26, 2022

POMES Syndrome, Relapsed and Refractory POMES Syndrome Trial in Shanghai (anti-CD19/BCMA CAR-T cells, Fludarabine,

Active, not recruiting
  • POMES Syndrome
  • Relapsed and Refractory POMES Syndrome
  • anti-CD19/BCMA CAR-T cells
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Aug 5, 2021

Relapsed Refractory Multiple Myeloma Trial (REGN5458, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Relapsed Refractory Multiple Myeloma
  • (no location specified)
Feb 6, 2023

Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial

Not yet recruiting
  • Recurrent B Acute Lymphoblastic Leukemia
  • +5 more
  • Interferon Beta-1A
  • +10 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 6, 2023

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023